WallStreetZenWallStreetZen

NASDAQ: LIXT
Lixte Biotechnology Holdings Inc Stock

$0.77+0.09 (+13.24%)
Updated Mar 21, 2023
LIXT Price
$0.77
Fair Value Price
$1.07
Market Cap
$12.80M
52 Week Low
$0.43
52 Week High
$4.95
P/E
-1.67x
P/B
2x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$6.71M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.06
Operating Cash Flow
-$5M
Beta
0.77
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

LIXT Overview

Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures for the treatment of cancers, and vascular and metabolic diseases; and LB-200 series to treat chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute. The company was founded in 2005 and is based in Pasadena, California.

Zen Score

Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how LIXT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

LIXT ($0.77) is undervalued by 28.41% relative to our estimate of its Fair Value price of $1.07 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
LIXT ($0.77) is significantly undervalued by 28.41% relative to our estimate of its Fair Value price of $1.07 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
LIXT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more LIXT due diligence checks available for Premium users.

Be the first to know about important LIXT news, forecast changes, insider trades & much more!

LIXT News

Valuation

LIXT fair value

Fair Value of LIXT stock based on Discounted Cash Flow (DCF)
Price
$0.77
Fair Value
$1.07
Undervalued by
28.32%
LIXT ($0.77) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
LIXT ($0.77) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
LIXT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

LIXT price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-1.67x
Industry
16.62x
Market
22.45x

LIXT price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
2x
Industry
4.85x
LIXT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

LIXT's financial health

Profit margin

Revenue
$0.0
Net Income
-$1.5M
Profit Margin
0%
LIXT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$6.8M
Liabilities
$408.3k
Debt to equity
0.06
LIXT's short-term assets ($6.82M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LIXT's short-term assets ($6.82M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LIXT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
LIXT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$1.2M
Investing
$0.0
Financing
$0.0
LIXT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

LIXT vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
LIXT$12.80M+13.09%-1.67x2.00x
UPC$12.85M+0.17%-1.48x0.28x
AEZS$12.92M+1.14%-1.04x0.26x
KTTA$12.66M+2.61%-1.88x0.27x
ACER$12.95M-6.94%-0.55x-1.06x

Lixte Biotechnology Holdings Stock FAQ

What is Lixte Biotechnology Holdings's quote symbol?

NASDAQ: LIXT) Lixte Biotechnology Holdings trades on the NASDAQ under the ticker symbol LIXT. Lixte Biotechnology Holdings stock quotes can also be displayed as NASDAQ: LIXT.

If you're new to stock investing, here's how to buy Lixte Biotechnology Holdings stock.

What is the 52 week high and low for Lixte Biotechnology Holdings (NASDAQ: LIXT)?

(NASDAQ: LIXT) Lixte Biotechnology Holdings's 52-week high was $4.95, and its 52-week low was $0.43. It is currently -84.46% from its 52-week high and 78.01% from its 52-week low.

How much is Lixte Biotechnology Holdings stock worth today?

(NASDAQ: LIXT) Lixte Biotechnology Holdings currently has 16,646,593 outstanding shares. With Lixte Biotechnology Holdings stock trading at $0.77 per share, the total value of Lixte Biotechnology Holdings stock (market capitalization) is $12.80M.

Lixte Biotechnology Holdings stock was originally listed at a price of $3.74 in Nov 25, 2020. If you had invested in Lixte Biotechnology Holdings stock at $3.74, your return over the last 2 years would have been -79.44%, for an annualized return of -54.66% (not including any dividends or dividend reinvestments).

How much is Lixte Biotechnology Holdings's stock price per share?

(NASDAQ: LIXT) Lixte Biotechnology Holdings stock price per share is $0.77 today (as of Mar 21, 2023).

What is Lixte Biotechnology Holdings's Market Cap?

(NASDAQ: LIXT) Lixte Biotechnology Holdings's market cap is $12.80M, as of Mar 22, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Lixte Biotechnology Holdings's market cap is calculated by multiplying LIXT's current stock price of $0.77 by LIXT's total outstanding shares of 16,646,593.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.